The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs - Trial NCT06325826
Access comprehensive clinical trial information for NCT06325826 through Pure Global AI's free database. This phase not specified trial is sponsored by Egyptian Liver Hospital and is currently Recruitment Completed. The study focuses on Hepatocellular Carcinoma. Target enrollment is 500 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Egyptian Liver Hospital
Timeline & Enrollment
N/A
Feb 01, 2022
Jun 30, 2025
Primary Outcome
Hepatocellular Carcinoma
Summary
This cohort study aims to evaluate the validation of general evaluation score in the
 prediction of hepatocellular carcinoma risk among patients with advanced fibrosis (F3) and
 cirrhosis (F4) who achieved sustained virological response for hepatitis c virus after direct
 acting antiviral drugs and determine the group of these patients who require intensified
 surveillance.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06325826
Non-Device Trial